Catalyst Pharmaceuticals, Inc. (CPRX)
| Market Cap | 2.67B |
| Revenue (ttm) | 534.65M |
| Net Income (ttm) | 197.35M |
| Shares Out | 121.98M |
| EPS (ttm) | 1.57 |
| PE Ratio | 13.93 |
| Forward PE | 15.52 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,001,355 |
| Open | 21.43 |
| Previous Close | 21.63 |
| Day's Range | 21.31 - 22.06 |
| 52-Week Range | 15.26 - 26.58 |
| Beta | 0.66 |
| Analysts | Strong Buy |
| Price Target | 32.83 (+50.25%) |
| Earnings Date | Aug 6, 2025 |
About CPRX
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatmen... [Read more]
Financial Performance
In 2024, Catalyst Pharmaceuticals's revenue was $491.73 million, an increase of 23.49% compared to the previous year's $398.20 million. Earnings were $163.89 million, an increase of 129.50%.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for CPRX stock is "Strong Buy." The 12-month stock price target is $32.83, which is an increase of 50.25% from the latest price.
News
Top 3 Health Care Stocks You'll Regret Missing This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Strong Inflows Make Catalyst Stock an Outlier
Catalyst Pharmaceuticals, Inc. (CPRX), keeps growing, bringing in Big Money.
Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer
Gary Ingenito, MD, PhD is retiring from Catalyst after a successful career Gary Ingenito, MD, PhD is retiring from Catalyst after a successful career
Catalyst: Solid Business Model Propels Growth For This Buy And Build Pharma
FIRDAPSE continues to drive strong performance, with Q1 2025 revenue and EPS both beating analyst expectations significantly. Catalyst reaffirmed its 2025 FIRDAPSE revenue guidance of $355–$360 millio...
Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2025 Earnings Call Transcript
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Michael Kalb - Executive Vice President & Chief Financial Officer Richard Dal...
Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update
Catalyst Enters 2025 With Strong Momentum; Reiterates Confidence in Full-Year Outlook Delivers Record Q1 2025 Total Revenues of $141.4 Million, a 43.6% YoY Increase FIRDAPSE® and AGAMREE® Drive Sustai...
Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025
CORAL GABLES, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, de...
Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025
The Company will Host a Conference Call and Webcast on May 8, 2025, at 8:30 AM ET The Company will Host a Conference Call and Webcast on May 8, 2025, at 8:30 AM ET
Catalyst Pharmaceuticals Announces Health Canada's Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals
CORAL GABLES, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, de...
Strong Revenue, Drug Performance Lift Catalyst Shares
Big Money continues buying Catalyst Pharmaceuticals, Inc. (CPRX).
Catalyst Pharmaceuticals: Undervalued Future With Multiple Upside Catalysts
Catalyst Pharmaceuticals' current stock price only assumes historical momentum for existing drug portfolio continues, undervaluing future upside potentials. CPRX stock's upside potential is driven by ...
Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference
CORAL GABLES, Fla., March 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, de...
Catalyst Pharmaceuticals: Stable Firdapse, Promising Agamree, Fycompa Challenges
Firdapse drives Catalyst Pharmaceuticals, Inc.'s revenue with a 37% CAGR since its 2019 launch, boosted by an FDA-approved 100 mg dose expansion. Agamree targets DMD and has so far generated $46 milli...
Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2024 Earnings Call Transcript
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Michael Kalb - Executive Vice President & Chief Financial Officer Richa...
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Full Year 2024 Total Revenues of $491.7 Million, Marking Another Year of Record Growth Full Year 2024 Total Revenues Grew 23.5% YoY, Driven by Strong Commercial Performance Q4 2024 Net Product Revenue...
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
CORAL GABLES, Fla., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev...
Catalyst Remains a Big Money Favorite
Catalyst Pharmaceuticals, Inc. (CPRX) shares keep gaining on Big Money buys.
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies
CORAL GABLES, Fla., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced its inclusion in Forbes' esteemed list of America's Most S...
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan
CORAL GABLES, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev...
Catalyst Pharmaceuticals: The Stars Align For Flagship FIRDAPSE
Catalyst Pharmaceuticals' investment merits are bolstered by a favorable settlement announced on 01/08/2025. CPRX generates income from three products, primarily FIRDAPSE for LEMS and FYCOMPA for epil...
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals
As Part of the Settlement, Teva Receives a License to Market Generic FIRDAPSE Beginning in February 2035 As Part of the Settlement, Teva Receives a License to Market Generic FIRDAPSE Beginning in Febr...
Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CORAL GABLES, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev...
Catalyst Pharmaceuticals Recognized as One of North America's Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List
Attributes 234% Revenue Growth to Operational Excellence and Strong Commercial Execution Attributes 234% Revenue Growth to Operational Excellence and Strong Commercial Execution
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
CORAL GABLES, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev...